Form 8-K - Current report:
SEC Accession No. 0001193125-21-225743
Filing Date
2021-07-27
Accepted
2021-07-27 16:41:01
Documents
16
Period of Report
2021-07-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d194030d8k.htm   iXBRL 8-K 37626
2 EX-99.1 d194030dex991.htm EX-99.1 21853
7 GRAPHIC g194030g0727232806226.jpg GRAPHIC 3675
8 GRAPHIC g194030g0727232806398.jpg GRAPHIC 3051
  Complete submission text file 0001193125-21-225743.txt   242020

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA amgn-20210727.xsd EX-101.SCH 4370
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE amgn-20210727_def.xml EX-101.DEF 13774
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE amgn-20210727_lab.xml EX-101.LAB 22822
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amgn-20210727_pre.xml EX-101.PRE 14743
9 EXTRACTED XBRL INSTANCE DOCUMENT d194030d8k_htm.xml XML 6355
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 211118060
SIC: 2836 Biological Products, (No Diagnostic Substances)